More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus, which has sickened more than 6 million Americans. The lapses leave officials and the public in the dark about the true scope of the pandemic as untold numbers of cases go uncounted.

Amunix turned heads back in March when it raised $73 million in a series A funding round that effectively transformed the company from a technology licenser to a biotech innovator. Amunix has been around since 2006, offering its half-life-extension technology to other biopharma developers. The funding allowed it to apply its tools to develop drugs that harness the immune system’s T cells to attack solid tumors.

Diagnostic maker Cellex has announced plans to develop a rapid coronavirus infection test that people can fully perform at home, from sample collection to result—with 15-minute readings double-checked by a personal smartphone app.

Companies are searching high and low for ways to make checkpoint inhibitors work for more people. One solution Merck is trying out is combining different checkpoint blockers—and early data from its TIGIT-blocking prospect and blockbuster PD-1 med Keytruda are promising.